Research on Cancer (IARC) evaluated the carcinogenicity of (30 out of 70, i.e. 42.9%). Moreover, most positive studies chromium and chromium compounds (1). As I will comment used administration routes which do not mimic any human in the present article, nothing new has happened in this decade exposure and by-pass physiological defense mechanisms.
chromium(VI) traces, as recognized by the authors themselves,
Out of the studies reviewed by the IARC (1), 12 results obtained with metallic chromium and 20 results obtained with only 42 out of 203 data (20.6%) were positive. In most studies, chromium(III) compounds (chromic acetate, chromic oxide, the purity of chromium(III) compounds had not been checked, chromic chloride, chrome tan or basic chromic sulfate, and positive results could often be ascribed either to artifacts chromic sulfate and chromite) were negative, irrespective of or to lack of validation of the test system. In any case, the the administration route. Similarly, 27 results available with doses needed for chromium(III) compounds to generate positive chromium-containing mixtures and other chromium comdata were two or three orders of magnitude higher than those pounds, one of which relative to chromium(IV) dioxide, were needed for chromium(VI) compounds to yield the same results consistently negative. Only one sample of roasted chromite (1,3). Chromium(0), in the form of chromium carbonyl, is also ore, in which chromium(III) was likely to have been oxidized devoid of mutagenicity in vitro (5).
to chromium(VI), was weakly carcinogenic in rats after intraTherefore, there is overwhelming evidence indicating that, pleural injection (1). Therefore, there is solid documentation at variance with chromium(III), chromium(VI) compounds that metallic chromium and chromium(III) compounds are are genotoxic and potentially capable of initiating cancer.
devoid of carcinogenicity in laboratory animals. Unfortunately, short-term tests do not contribute to the Several chromium(VI) compounds were assayed for carcinoelucidation of which chromium(VI) compounds possess these genicity. Only a minority of the available results (30 out of properties in whole organisms, which depends on the avail-70, i.e. 42.9%) were positive (1), which is a rather unexpected ability of chromium(VI) to target cells, as a function of outcome if one takes into account the consistent genotoxicity solubility of compounds and of toxicokinetic and metabolic of chromium(VI) when challenged in vitro with target cells. mechanisms.
Besides the low frequency of positive results, other patterns The differential toxicological relevance of these chromium are evident. The first is that there is a cluster of positive results species mainly depends on the fact that chromium(VI), in corresponding to chromium(VI) compounds of intermediate the form of chromate anion, which predominates over the solubility, such as calcium chromate, strontium chromate and dichromate anion at physiological pH, is easily taken up via zinc yellow (basic zinc chromate). Another feature is that the the general anion channel protein or band 3 protein. In majority of positive results were generated in studies in which contrast, cellular membranes are normally impermeable to chromium(VI) compounds were given by certain administrachromium(III) cations, which can penetrate into cells only tion routes (subcutaneous, intramuscular, intraperitoneal, intraunder particular conditions (6).
pleural, intrabronchial) which not only do not reproduce any human exposure but also by-pass important detoxification Biomarkers of exposure and effect in humans mechanisms of the organsim. In addition, all positive results Chromium levels in the blood and urine are biomarkers of expowere rather weak and were generated at single, high doses. sure, reflecting the amount of chromium which is internalized When more than one dose was tested, no dose-response curve in the body. However, whereas chromium in erythrocytes is could be drawn. In addition, chromium(VI) only induced local diagnostic for internal exposure to chromium(VI), it is not tumors at the administration site, and not at a distance from possible to distinguish, on the basis of urinary chromium, the portal of entry into the organism. The only exception was whether exposure to chromium(VI) or chromium(III) has a study (13) in which intramuscular injections of lead chromate occurred (7). In fact, as the result of chromium(VI) reduction in in rats resulted in the development of renal carcinomas. the blood, all chromium detectable in the urine of exposed However, as commented by the IARC Working Group (1), individuals is chromium(III) (1,8,9). this effect should be ascribed to the lead moiety, which A number of studies evaluated the problem of biological typically produces kidney tumors in rodents (14). monitoring by assessing cytogenetic end-points, such as All these patterns are consistent with the occurrence of chromosomal aberrations, sister chromatid exchanges and threshold mechanisms in chromium(VI) carcinogenesis. micronuclei, in lymphocytes of chromium-exposed workers.
Chromium-contaminated environmental samples In spite of the consistent genotoxicity of chromium(VI) comBesides several results obtained with mixed chromium dust, pounds in in vitro test systems, the majority of cytogenetic all of them negative (1), a recent study (15) specifically surveillance studies among chromium platers, ferrochromium addressed the problem of evaluating the carcinogenicity in rats workers and stainless steel welders have yielded negative or of a soil, which was heavily contaminated with chromium(VI) inconclusive results (reviewed in ref. 7). Similarly, either (almost 6 g/kg soil). The soil sample was collected from positive results or negative results were obtained by measuring Hudson County, NJ, which, during much of this century, was DNA single-strand breaks in the lymphocytes of chromiuma major center for the processing of chromium ore. After exposed workers (10). No oxidative DNA damage occurred in repeated intratracheal instillations, no tumor was detected in chromium(VI) production workers (11) , and no significant rats treated with either control soil or Hudson County soil, the increase of DNA-protein crosslinks was observed in chromium latter receiving a total of 324 µg chromium(VI)/kg body platers (12) .
wt. In the same study, intratracheal instillations of calcium chromate, for a cumulative dose of 8.7 mg/kg, and of Hudson County soil supplemented with calcium chromate, for a total Evaluation of chromium carcinogenicity in laboratory of 8.0 mg/kg, produced four and one lung tumors, respectively. animals These data were not statistically significant (15) .
Chromium compounds
Carcinogenicity of chromium to humans A number of studies were carried out during the past 45
Categorization of chromium compounds according to carcinoyears in order to evaluate the carcinogenicity of chromium genicity compounds of various solubility and oxidation states in rodents (mainly rats and mice but also hamsters, guinea pigs and According to the World Health Organization (WHO), 'chromium(III) is not considered to be carcinogenic' (16) . The rabbits).
IARC evaluated that 'there is inadequate evidence in humans ruled out any role of contamination with these metals of for the carcinogenicity' of chromium(0) and chromium(III) drinking water from a municipal supply (25) . compounds. Also based on the results of animal carcinogenicity Target organs studies, the overall evaluation was that chromium(0) and As specified previously, the epidemiological studies carried chromium(III) 'are not classifiable as to their carcinogenicity out in certain occupational settings consistently show that to humans (Group 3)' (1).
(unidentified) chromium(VI) compounds can be carcinogenic In contrast, chromium(VI) has been known to be an occupafor the lower respiratory tract. Moreover, a few studies reported tional carcinogen for more than a century (17) . The IARC an association between exposure to chromium(VI) and cancers evaluated that 'there is sufficient evidence in humans for the of the sinonasal cavity. An increased mortality for cancers at carcinogenicity of chromium(VI) compounds', as encountered other sites was sporadically reported, which was counterin specific occupational settings. The overall evaluation was balanced by several studies in which the risk of developing that 'chromium(VI) is carcinogenic to humans (Group 1)', as cancer at various sites was apparently decreased in chroinferred from 'the basis of the combined results of epidemiomium(VI)-exposed individuals. Clearly, these findings reflect logical studies, carcinogenicity studies in experimental animals, the lack of consistency of some data generated in epidemioand several types of other relevant data which support the logical studies performed in relatively small groups of exposed underlying concept that chromium(VI) ions generated at critical workers. Moreover, most occupations involved exposures not sites in target cells are responsible for the carcinogenic action only to chromium(VI) compounds but also to other recognized observed' (1). The US Environmental Protection Agency carcinogens, such as other metals (e.g. nickel), organic com-(USEPA) has also classified chromium(VI) in Group A, that pounds (e.g. polycyclic aromatic hydrocarbons), fibers (e.g. is a human carcinogen (18) . asbestos) and complex mixtures (e.g. cigarette smoke). It is Workers at risk thus important to discriminate the effects of confounding A number of occupational activities involve the production or factors and to pinpoint those findings that are validated by the use of chromium or chromium compounds (1). An estimated converging evidence provided by different epidemiological 305 000 workers in the USA are potentially exposed to studies. chromium and chromium-containing compounds in the workBased on these considerations, in 1988 the WHO concluded place (19) .
that 'there is insufficient evidence to implicate chromium as a The epidemiological evidence for an increased risk of causative agent of cancer in any organ other than the lung' respiratory cancer in chromium(VI)-exposed workers was (16) . In 1990, the IARC concluded that 'for cancers other than provided under conditions of high exposure, as encountered of the lung and sinonasal cavity, no consistent pattern of cancer in the chromate production, chromate pigment production and risk has been shown among workers exposed to chromium chromium plating industries, which in the past decades mainly compounds' (1). This conclusion was reiterated, almost involved mixed exposures to various chromium(VI) comverbatim, in a review article published 3 years later (26) . A pounds and possibly to other metals as well as organic recent authoritative article on carcinogenicity of metals in substances. In contrast, no evidence is available for carcinohumans (20) further emphasized the selective carcinogenicity genicity of chromium in other occupational categories of chromium(VI) in the lung and nasal cavity of workers in (1, 19, 20) . The epidemiological studies do not clearly implicate chromate production, chromate pigment production and chrome specific compounds, but do implicate chromium(VI) complating. In the same year, however, another review article pounds (19) .
claimed that chromium(VI) can be involved in the causation Environmental exposures of a broad spectrum of additional cancers, including prostate cancer, lymphoma, leukemia, and bone, stomach, brain, kidney There is no evidence that chromium causes cancer in humans and testicle cancers (27). This position is surprising not only following environmental exposures. According to WHO, 'there for the lack of scientific support, as discussed below, but also is not reason, at present, to be concerned that chromium in because the same author had been a member of the IARC the air presents a health problem, except under conditions of Working Group (1) and had 4 years earlier co-authored industrial exposure' (16) .
the article (26) supporting the selective carcinogenicity of A retrospective environmental epidemiological study in chromium(VI) to the human lung and sinonasal cavity. Sweden 'could not demonstrate an increase in lung cancer Eleven epidemiological studies were cited by Costa (27) to mortality among a population exposed to exhaust from support the broad target carcinogenicity of chromium(VI) in ferrochromium industries' (21) . Two studies raised the suspihumans. Four of these studies (28-31) had previously been cion that contamination of water with chromium(VI) could be evaluated by the IARC (1), whereas the remaining seven associated with an increased mortality for cancer, but in both studies (24, (32) (33) (34) (35) (36) (37) ) are more recent. The possible exposures cases the same authors ruled out this hypothesis. Thus, after were extremely heterogeneous, and in most instances they also a preliminary study reporting increased incidences of cancer included agents other than chromium. Ten studies (28-37) in a population who resided in a polluted area near an alloy covered seven different occupational settings, whereas one plant that smelted chromium in the People's Republic of China study referred to a possible exposure to groundwater con- (22) , no chromium-related increases in stomach cancers or taminated with arsenic and chromium (24) . It is noteworthy overall cancer mortality could be documented in a more that the responsibility of these metals for the increased mortality accurate evaluation (23) . Between 1966 and 1986, the childof leukemia in children and youngsters had been presented as hood leukemia rate in Woburn, MA, was higher than the a working hypothesis (24) , which was later demonstrated to national average (24) . This finding prompted a multidisciplinbe unjustified by the same group (25) . ary research team from MIT, which was supported by the The Costa (27) paper suffers from a number of inaccuracies NIEHS Superfund Basic Research Program. Measurement of arsenic and chromium in hair samples from Woburn residents and gross mistakes, regarding references, working categories, identity or definition of cancer sites and report of data. tissues and organs, such as liver, peripheral lung parenchyma, Moreover, Costa (27) arbitrarily selected those data which bronchial tree, cutis, subcutis, kidney, testis, stomach, intestine, could be of some use to support his theories, i.e. just two data spleen, bladder and adrenals (5,6,45). for prostate cancer, one for cancer of the haemolymphopoietic The chromium(VI) reducing capacity, as inferred from ex system, one for Hodgkin's disease, three for leukemia, one for vivo studies, was expressed in quantitative terms in each bone cancer, five for stomach cancer, four for brain cancer, study. Based on these data, we recently made quantitative one for bladder cancer, two for renal cancer and two for genital estimates of the overall reducing capacity of chromium(VI) in cancer. In contrast, he disregarded other data reported in the some human body compartments by relating the specific same papers, many of which showed negative or even opposite reducing activity of body fluids, cell populations or organs to trends. For instance, in one study only (30) was there a their average volume, number or weight (45). Reduction of significant increase of stomach cancer deaths, and in white chromium(VI) in body fluids and non-target cells is expected workers only, while in another study (36) the observed stomach to greatly attenuate or eliminate its potential toxicity and cancer deaths were significantly lower than expected. Therecarcinogenicity, to imprint a threshold character to the carcinofore, in spite of exposures to chromium(VI) compounds of genesis process, and to restrict the possible targets of its activity. workers by the oral route, due either to impact of large size
Metabolism of chromium(VI) in target cells particles onto the oropharyngeal mucosa or to swallowing of
The overall evaluation of the IARC Working Group on particles refluxed from the respiratory tract via the mucochromium(VI) compounds underlies the 'concept that ciliatory escalator, recent data are consistent with the consensus chromium(VI) ions generated at critical sites in the target reached by the IARC Working Group (1) that there is no cells are responsible for the carcinogenic action observed' (1). consistent indication in the literature supporting an increased This concept was reiterated verbatim by the US Department risk of stomach cancer.
of Health and Human Services (19) . Which are target cells? Very few of the increases in mortality rates claimed by They are those cells which can be exposed to chromium(VI) Costa (27) are statistically significant, and in most cases escaping upstream reduction in body fluids and non-target they appear to be biologically irrelevant and due to chance.
cells. Therefore, as previously discussed, any prokaryotic or Occasional decreases of the mortality rates or even, in many eukaryotic cell can be the target for chromium(VI) genotoxicity cases, the unexpected lack of deaths for cancers at given sites in vitro; in animal carcinogenicity assays, target cells are those should be interpreted in the same way. No cancer in the where chromium(VI) is locally applied; in humans exposed to sinonasal region was reported in any of these studies, and high doses of chromium(VI), target cells are those of the even cancers in the lower respiratory tract were significantly respiratory tract, provided chromium(VI) is successful in increased in a limited number of studies, including one only overwhelming the defense mechanisms of airways. Thus, the of two studies in chrome platers (29) , one only of two studies selection between target cells and non-target cells is operated in workers exposed to lead and zinc chromate pigments (32) by toxicokinetic factors affecting reduction of chromium(VI). and one study in zinc chromate painters (31) . On the other Once in touch with cells, the chromate anion easily crosses hand, no significant excess risk was observed in two studies cell membranes (6), after which chromium(VI) tends to be in ferrochromium workers (33, 34) , one study in welders (35) reduced inside the cell. Thus, chromium(VI) functions as a and one study in tanners (36) . On the whole, these recent sort of Trojan horse, allowing penetration of chromium into data fully support the selective respiratory carcinogenicity the cell. Other types of cellular uptake, such as internalization of chromium(VI) compounds in the three aforementioned of insoluble particles, have also been shown to occur in vitro categories of chromium(VI)-exposed workers (1, 19, 20) .
(46). Chromium(VI) is reduced in different cell compartments. According to our studies, reduction in the cell cytosol is greater Mechanistic interpretations based on chromium(VI) than in the endoplasmic reticulum and in mitochondria and toxicokinetics and metabolism the nucleus (47) . Chromium(VI) reduction is a composite Reduction of chromium(VI) in body fluids and non-target cells process due to a network of mechanisms, which involve the contribution of reducing molecules, such as ascorbate, The chromium(VI) reducing capacity of rat liver preparations glutathione (GSH), cysteine, hydrogen peroxide and riboflavwas shown independently Ͼ20 years ago by Gruber and ine, as well as enzyme-catalyzed reactions, e.g. by cytochrome Jennette Wetterhahn (38) and in my laboratory (39,40) using P450, aldehyde oxidase and DT diaphorase (reviewed in ref. 6). analytical tecniques and mutagenicity assays, respectively. At Reduction of chromium(VI) results in the formation of the same time, we demonstrated that it is not possible to chromium(III), the stable reduced form, which binds DNA oxidize inactive chromium(III) to mutagenic chromium(VI) by more efficiently than chromium(VI) (3). Moreover, intermeans of a variety of rat and human metabolic systems (41) . mediate reduced products, i.e. chromium(V) and chroAfter that, we evaluated the chromium(VI) reducing capacity mium(IV), are also suspected to play a role in chromium of metabolic systems derived from humans and a variety of genotoxicity and carcinogenicity, either per se or through other animal species, including rodents (mice, rats, hamsters, reaction with other cellular components resulting in the generawoodchucks), avian species (chicken, Pekin duck) (reviewed tion of reactive oxygen species, and in particular of the in ref. 6), freshwater fish (42), seawater fish (43) and even hydroxyl radical (OH·) (reviewed in ref. 6). Oxidative DNA marine sponges (44) . Using either analytical techniques and/ damage is detectable after exposure of cells to chromium(VI) or mutagenicity assays, we evaluated the fate of chromium (VI) in vitro (6,46,48,49), and we have recently shown its occurrence after challenge with body fluids, such as saliva, gastric juice in vivo in lung cells but not in liver cells of rats receiving and epithelial-lining fluid (ELF); microorganisms colonizing i.t. instillations of chromium(VI) (50). Unfortunately, many the human body, such as intestinal bacteria; isolated cells, such studies using acellular systems, in which chromium(VI) and a as red blood cells (RBC) and bronchoalveolar lavage cells, mainly consisting of pulmonary alveolar macrophages (PAM); reducing system are mixed together in a tube, in close contact with pure DNA, do not take into account the extreme reduction in volunteers (53) . Reduction of chromium(VI) by reactivity of OH·, which does not live Ͼ1 ns and does not gastric juice is due to thermostable components of gastric travel Ͼ1 nm (51). Therefore, this mechanism is likely to secretions, and is favored by low pH. The reaction is complete work in whole cells only when OH· generation occurs in very within 10-20 min, and at least half of it is accomplished in close contact with DNA. Several types of DNA damage occur 1 min (45). We also estimated that the daily removal of in chromium(VI)-exposed cells, including single-strand breaks, chromium(VI) with fecal bacteria is 15.4-33.4 mg/individual DNA-DNA interstrand crosslinks, DNA-protein crosslinks, (45). Intestinal bacteria contain high amounts of GSH (54), chromium-DNA adducts, oxidative nucleotide changes and which is an efficient reductant for chromium(VI) (6). Since chromosomal aberrations (6,46). bacterial GSH is released extracellularly (54), it is likely that Chromium(VI) reduction in target cells may be variously chromium(VI) is additionally reduced in the intestinal lumen. interpreted. When Gruber and Jennette Wetterhahn (38) showed Reduction of chromium(VI) in the digestive tract explains that chromium(VI) can be reduced by rat liver P450 enzymes, why, in both humans and animal models, there is a very they raised the hypothesis that this is an activating mechanism.
poor intestinal absorption of orally introduced chromium(VI) This theory (reduction-activation) is quite plausible since, as (8, (55) (56) (57) . In case chromium(VI) may escape reduction by just discussed, the reduced species are the most likely DNAsaliva and gastric juice, sequestration by intestinal bacteria damaging agents. In the same year, I demonstrated that rat and, probably, other mechanisms that we did not investigate, liver preparations decrease chromium(VI) mutagenicity (39) , it will be absorbed by the intestine, released into the blood of and I interpreted this finding as a detoxification mechanism.
the portal system, and carried to the liver. As described below, This theory (reduction-detoxification) is also supported by the blood, and in particular RBC, has a considerable capacity several lines of evidence, such as the fact that tissues or organs, of sequestering and reducing chromium(VI). The human liver such as the liver, which are not the target for chromium (VI) can reduce as much as 3.3 g chromium(VI)/individual (45). carcinogenicity, are characterized by a potent chromium(VI)
Although it is impossible to estimate the daily reduction, it reducing capacity in a broad spectrum of animal species. In should be kept in mind that many of the chemical and contrast, typical targets for chromium(VI) carcinogenicity biochemical mechanisms accounting for chromium(VI) reducin rodent assays, such as the rat skeletal muscle, have a tion in the liver are continuously renewed. negligible effect on chromium(VI) mutagenicity (40). There-
The acute oral toxicity of chromium(VI) is rather low, the fore, tissue-specific susceptibility to chromium(VI) carcino-LD 50 in rodents being Ͼ50 mg chromium(VI)/kg body wt genicity correlates with intrinsically poor capacity for (58). Few lethal effects were observed in episodes of accidental intracellular chromium(VI) reduction. Probably, both theories ingestion or tentatives of suicides with high doses of chroare valid. When in 1989 Karen Wetterhahn and myself mium(VI). For instance, following ingestion of chromium(VI) prepared an extensive review article covering the mechanisms compounds in the 8-20 g range, eight subjects survived and of chromium metabolism and genotoxicity, we tried to harmonthree subjects died (59). Oral chromium(VI) is not genotoxic ize our positions (see Chapter 7.3 and Figure 54 of ref. 6) .
at doses which greatly exceed the drinking water standards. We reached a consensus that the intracellular chromium(VI)
Thus, ingestion of a bolus dose of 5 mg chromium(VI) by reduction, leading to generation of reactive species, may be human volunteers did not result in any increase of DNAviewed as an activation process, when it occurs in the proximity protein crosslinks in peripheral blood lymphocytes (60). of DNA. Alternatively, reduction is a detoxification process Administration of up to 20 mg chromium(VI), either in drinking when it occurs far away from DNA, and the reactive species water or by gavage, failed to produce any effect in the mouse can be trapped by a large number of ligands, nucleophiles and bone marrow micronucleus assay or in the rat hepatocyte antioxidants which are present in the intracellular environment.
DNA repair assay (61). As discussed previously, the lack of Therefore, the cellular site of reduction is crucial in affecting carcinogenicity of chromium by the oral route is supported the fate of the cell taking-up chromium(VI) (6). It is also both by animal studies and epidemiological data. As to noteworthy that chromium(VI)-exposed cells can undergo other health effects resulting from long-term exposures to apoptosis (46) as a consequence of DNA damage, and therefore chromium(VI) with drinking water, no adverse effect was are eliminated from the organism. observed in dogs fed 11.2 mg/l chromium(VI) for 4 years (62) or rats fed 25 mg/l for 1 year (63) or 134 mg/l for 6 months (64). Moreover, no health effect was reported in a family Fate of chromium(VI) in the organism accidentally exposed to chromium(VI) at 1 mg/l in well water Exposure by the oral route for 3 years (65). Chromium(VI) can be ingested with drinking water, other
Exposure by inhalation beverages and food. Certainly, many food components have
The respiratory tract is the only target for chromium(VI) reducing properties. It has been shown that chromium(VI) is carcinogenesis in individuals performing certain occupational efficiently reduced when drinking water is used to prepare activities, which involve exposures to levels in air that were common beverages (52). Another way of exposure of the several orders of magnitude higher than those found in the digestive tract is swallowing of chromium(VI) refluxed from natural environment (1,19). This conclusion, together with airways via the muco-ciliatory escalator in individuals exposed the inconsistent positive results obtained in rodents exposed by inhalation.
to chromium(VI) by inhalation or intratracheal instillation, Ex vivo studies performed in my laboratory documented suggests that respiratory cancer can only be induced by the chromium(VI)-reducing capacity of the human digestive chromium(VI) doses which overwhelm the body's defense tract (45). In particular, we estimated that saliva reduces mechanisms. It is well known that the respiratory tract has 0.7-2.1 mg chromium(VI)/individual/day and gastric juice important non-specific defense mechanisms (66) . In addition, reduces at least 80.3-84.5 mg chromium(VI)/individual, as assessed by evaluating the circadian course of chromium(VI)
we demonstrated that chromium(VI) reducing mechanisms occur in the lower respiratory tract. In particular, the ELF, Moreover, the PAM from current smokers exhibited a chromium(VI) reducing capacity which was significantly including the surfactant and bronchial-bronchiolar secretions which can be recovered by bronchoalveolar lavage, has an higher than that of either ex-smokers or never smokers (67) . Similarly, preparations of peripheral lung parenchyma from overall reducing capacity of 0.9-1.8 mg chromium(VI) (45,67). The ELF of both humans (68) and rats (69) is known to be smokers were significantly more efficient than those from non-smokers in decreasing chromium(VI) mutagenicity (72) . particularly rich in antioxidants.
PAM are sweeping cells which can reduce~2 µg chroTherefore, there are some lines of evidence suggesting that, at least in certain steps of the carcinogenesis process, there is a mium(VI)/10 6 cells in rats (70) and 4.4 µg chromium(VI)/10 6 cells in humans (67) . Based on the knowledge that 23ϫ10 9 less than additive effect between chromium(VI) and cigarette smoke. Recently, using an acellular system, i.e. by reacting a PAM populate terminal airways in humans, we estimated an overall chromium(VI) reducing capacity of 136 mg per CSC, chromium(VI) and plasmid DNA, it was shown that this mixture results in an enhanced generation of OH· radicals and individual (45). Since 1-5ϫ10 6 PAM are removed every hour from human terminal airways via the muco-ciliatory escalator induction of DNA single-strand breaks (77). However, as discussed previously, this type of study suffers from the (66), it can be calculated that the PAM population which is renewed every day will reduce 0.1-0.5 µg chromium(VI).
limitation that OH· generation is artificially achieved in close contact with DNA rather than in a whole organism. We have Thus, even in cases of long-term exposure, which require a continuous detoxification of inhaled chromium(VI), the now in progress a study in rats exposed whole-body to cigarette smoke and/or treated intratracheally with chromium respiratory tract appears to have efficient reducing mechanisms, which, however, are not as formidable as those of the diges-(VI). We will evaluate several biomarkers, including oxidative DNA damage, DNA-protein crosslinks, smoke-related and tive tract.
Human bronchial tree (71) and peripheral lung parenchyma chromium(VI)-related DNA adducts in lung cells, and cytogenetic damage in PAM and bone marrow cells. The results (72) showed a notable chromium(VI) reducing activity. Since these tissues are possible targets for chromium(VI) carcinoof cytogenetic analyses clearly showed that the combined exposure to cigarette smoke and chromium(VI) is less than genicity, the outcome of the chromium(VI) reduction, either activation or detoxification, will depend on the intracellular additive in enhancing the frequency of micronuclei in PAM and bone marrow cells (R. Balansky, F. D'Agostini, A. Izzotti site where the process is accomplished. Since peripheral lung parenchyma reduces on average 0.2 mg chromium(VI)/g (72), and S. De Flora, manuscript in preparation). and the human lungs weigh 1300 g, we estimated an overall Dermal exposure chromium(VI) reducing capacity of 260 mg per individual (45).
Together with inhalation and oral penetration, dermal
Auto-induction of chromium(VI) metabolism in the lung
contact is the only possible route of exposure of humans to chromium(VI). It is well known that direct skin contact with An interesting issue is the possible modulation of the pulmonary metabolism of chromium(VI) and occurrence of interactions chromium(VI) may produce irritating and ulcerating effects and elicit an allergic response, characterized by eczema and with other inhalable carcinogens. We demonstrated that repeated intratracheal instillations of sodium dichromate in dermatitis, in sensitized individuals (19) . No studies were located regarding cancer in humans or animals after exposure rats, according to a schedule which failed to induce lung tumors (73), result in an auto-induction of chromium (VI) to chromium compounds (19) . However, it is very likely that at least a proportion of workers involved in chromium metabolism in the lung (74) . In other words, repeated exposures to chromium(VI) potentiate its own metabolism in the lung production and use were exposed not only via the respiratory route but also by the oral route and by the dermal route as (74) , and this correlates with failure to induce lung tumors under the same experimental conditions (73). Incidentally, this well. In this connection, it is noteworthy that no significant increase in mortality for skin cancer (35) or specifically for is a further finding which supports the role of chromium(VI) reduction in lung cells as a detoxification mechanism. malignant melanoma (33) could be detected in chromium(VI)-exposed workers.
Interaction between chromium(VI) and cigarette smoke
Lack of carcinogenicity of chromium(VI) at a distance from The interaction between airborne exposure to chromium(VI) the penetration site and cigarette smoke is an intriguing problem, which was not clarified by epidemiological studies (17) . No synergistic effect As previously commented, it is typical that, even when chromium(VI) was successful in inducing tumors in between cigarette smoking and stainless welding was observed in the induction of chromosome damage in lymphocytes (75) . experimental animals, they only occurred at implantation sites. In humans, the respiratory tract is the only target Smokers usually show higher urinary chromium levels than non-smokers (7), which might be ascribed to enhanced retention for chromium(VI) carcinogenicity which was consistently documented by epidemiological studies. of particulates in the bronchial tree. Alternatively, this finding may be interpreted as a stimulation of chromium(VI) reduction
The explanation for the lack of carcinogenicity of chromium(VI) at a distance from the penetration site is in smokers, leading to an increased urinary excretion of chromium(III). In fact, we showed that a cigarette smoke that, in case chromium(VI) may escape detoxification in the respiratory tract, it will be released into the blood stream. condensate (CSC) decreased the mutagenicity of chromium(VI) in bacteria, presumably due to the presence of reducing Therefore, chromium can be transported to any organ via the blood circulation. In particular, while chromium(III) is agents in CSC. At the same time, chromium(VI) inhibited the metabolic activation of either CSC or benzo[a]pyrene to transported in the blood plasma, bound to proteins, such as transferrin (6), chromium(VI) is selectively accumulated in mutagenic derivatives (5). The antagonistic effect between chromium(VI) and benzo[a]pyrene diol epoxide was recently RBC. This is so typical that, for half a century, radioactive chromium ( 51 Cr) has been used to tag RBC (78). shown by also evaluating the frequency of HPRT mutants in cultured human fibroblasts (76) .
After penetration into RBC, chromium(VI) is reduced to chromium(III), especially by GSH, and bound to low were often less mutagenic in mammalian assays than in bacterial assays (26, 88) , which is likely to reflect the greater molecular weight components and chiefly to hemoglobin (6,8,52,57,79-83).
metabolic capacity of eukaryotic cells as compared with prokaryotic cells, resulting in more efficient detoxification. In 1978 we demonstrated that chromium(VI) mutagenicity is lost in the presence of human RBC lysates (40). Recently, Likewise, metabolic patterns can explain the lower DNA damage detected in a whole organism than in cultured cells, we evaluated that whole blood has an overall sequestering capacity of 234 and 187 mg chromium(VI)/individual, and as demonstrated even when analysing the same end-point in the same type of cells (93). In whole organisms, the potential that RBC reduce at least 138 and 100 mg chromium(VI)/ individual in males and females, respectively. The lifespan carcinogenicity of chromium(VI) compounds can be circumvented by the body's defense mechanisms. In humans, this (mean Ϯ SD) of human RBC is 107 Ϯ 12 days (84). Therefore, every day a population of 19 ml in males and 14 ml in females results in a specific localization of cancer to the respiratory tract, and only in those individuals who are exposed to will be renewed, thus accounting for at least 1.3 and 0.9 mg chromium(VI) reduced just by the proportion of RBC which massive doses of chromium(VI) in certain occupational settings. In animal models, the existence of threshold mechanis renewed daily. Also in 'old' RBC, however, there is a continuous replenishment of GSH, which is imported from the isms is strongly supported by the lack of carcinogenicity of chromium(VI) compounds in the majority of the studies liver (85) .
It is thus extremely unlikely that chromium(VI) can travel available in the literature. In positive studies, induction of cancer typically occurred under particular conditions overat a distance from the portal of entry into the organism without having been reduced to chromium(III) upstream in the blood. whelming the defense mechanisms, i.e. (i) at extremely high doses, yielding a yes or no response, without any graduation In fact, both in occupationally exposed workers (9) and in human volunteers drinking chromium(VI)-contaminated water of the effect; (ii) at implant sites only, and not at a distance from the portal of entry into the organism; (iii) in certain targets (8), all chromium detectable in urine was chromium(III). In experimental animals 'excretion occurs rapidly, and primarily only, selected by the potency of detoxification mechanisms; or (iv) when given in a single massive dose, and not in the same via the kidneys, once chromium(VI) is reduced. Thus, absorption, distribution, metabolism, and excretion of chromium is cumulative amount fractionated into smaller doses which can be more easily detoxified. These are exactly the patterns that, fairly well understood' (19) .
15 years ago, I proposed as general criteria for assessing the existence of thresholds in the case of genotoxic compounds Multiple lines of evidence supporting the occurrence of which tend to be detoxified in the organism (94).
threshold mechanisms in chromium(VI) carcinogenesis
The issue of thresholds in carcinogenesis, especially in the
